Georgia's Online Cancer Information Center

Head and Neck Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Head and Neck Cancer
Cancer Type = Head and Neck Cancer
There are currently 22 active Head and Neck Cancer clinical trials in Georgia.
2.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
NCORP Trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Head and Neck Cancer, Lung Cancer
NCT ID
NCT03329950
Protocol IDs
CDX1140-01
NCI-2018-00959
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
4.
A Phase I / II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and / or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCT ID
NCT03370276
Protocol IDs
MCC-19178
NCI-2017-02373
Treatment Sites (1)
5.
A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Cancer Type
Head and Neck Cancer, Oral Cancer
NCT ID
NCT02567422
Protocol IDs
9950
NCI-2015-01643
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
NCORP Trial
A Phase II / III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Cancer Type
Head and Neck Cancer
NCT ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients with RM SCCHN Who Have Failed Platinum Based Therapy
Cancer Type
Head and Neck Cancer, Oral Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
10.
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Oral Cancer
NCT ID
NCT01141231
Protocol IDs
97115
NCI-2011-02073
CDR0000674208
WF 97115
WFU-97115
MDA-04-01
11.
A Prospective, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Single-Dose Intraoperative Ketamine for the Prevention of Delirium in Otolaryngeal Cancer Surgery Patients
Cancer Type
Head and Neck Cancer, Oral Cancer
NCT ID
NCT03040024
Protocol IDs
EU3268-16
NCI-2017-00172
IRB00086609
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
12.
A Randomized Phase II / III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT03952585
Protocol IDs
NRG-HN005
NRG-HN005
NCI-2019-03015
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
13.
A Randomized, Phase II Study of Ficlatuzumab with or without Cetuximab in Patients with Cetuximab-Resistant, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCT ID
NCT03422536
Protocol IDs
1710965268
NCI-2017-02209
AVEO
AV-299-17-117i
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Cancer Type
Colon/Rectal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03783936
Protocol IDs
HCRN GI17-319
NCI-2018-03813
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
Phase 1 / 2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Cancer Type
Breast Cancer, Cervical Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN
Cancer Type
Head and Neck Cancer, Oral Cancer
NCT ID
NCT02101034
Protocol IDs
201404139
NCI-2014-01079
14-X031
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
18.
Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for P53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Cancer Type
Head and Neck Cancer, Oral Cancer
NCT ID
NCT02734537
Protocol IDs
EA3132
NCI-2015-01911
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT01311063
Protocol IDs
RTOG0920-VA
RAC# 2101-074
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
21.
Randomized Phase II / III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Cancer Type
Head and Neck Cancer, Oral Cancer
NCT ID
NCT03258554
Protocol IDs
NRG-HN004
NRG-HN004
NCI-2017-01522
Treatment Sites (3)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Cancer Type
Head and Neck Cancer
NCT ID
NCT02135042
Protocol IDs
NRG-HN001
NCI-2014-00635
RTOG-1305
U10CA180868
U10CA021661
Treatment Sites (4)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.